Fluicell

Fluicell Share Buybacks

Share Buybacks of Fluicell (FLUI.ST) as of Nov 20, 2026.

Share Buybacks

0.00SEK

Last updated:

Share Buybacks of Fluicell is 2025 0.00 SEK. Share Buybacks of Fluicell was 2024 39.51 M SEK. It decreases by % lower compared to the previous year.

The Fluicell Share Buybacks history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Share Buybacks
Date
Share Buybacks
Jan 1, 2018
33.68 M SEK
Jan 1, 2019
-6.40 M SEK
Jan 1, 2020
30.79 M SEK
Jan 1, 2021
23.20 M SEK
Jan 1, 2022
31.66 M SEK
Jan 1, 2023
3.87 M SEK
Jan 1, 2024
39.51 M SEK
Jan 1, 2025
0.00 SEK
The Fluicell Share Buybacks history
YEARShare BuybacksYoY
0.00SEK-100.00%
39.51 MSEK+920.77%
3.87 MSEK-87.77%
31.66 MSEK+36.47%
23.20 MSEK-24.64%
30.79 MSEK-581.08%
-6.40 MSEK-119.01%
33.68 MSEK+105.31%
16.40 MSEK+268,785.25%
6,100.00SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fluicell Stock analysis

What does Fluicell do? Fluicell AB commercializes research tools BioPen and Dynaflow Resolve for studying, processing, and measuring drug impact on individual cells in cell-based pharmacology research. The company also develops bioprinting technology Biopixlar Retina, offering 2D and 3D options to create complex tissue-like structures with precise cell positioning control. These products target drug development research segments where individual cell analysis is critical. The primary buyers are pharmaceutical companies and research institutions focused on cell-based pharmacology. Fluicell AB's product portfolio includes BioPen, Dynaflow Resolve, and Biopixlar Retina, all designed for cell-based pharmacology research applications. The company's tools enable detailed analysis of drug effects at the single-cell level, supporting pharmaceutical research and development processes. Biopixlar Retina specifically addresses tissue engineering needs by allowing controlled creation of tissue-like structures in both 2D and 3D formats. The company's revenue streams come from selling these research tools and bioprinting technologies to pharmaceutical companies and research institutions. These segments value the precision and control offered by Fluicell's products for cell-based drug development studies. The products are positioned as essential tools for advanced cell analysis in pharmacology research environments. Fluicell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fluicell stock

On Eulerpool you can find the complete historical development of Share Buybacks Fluicell since 2006 – with annual values, charts, and detailed analysis.

Share buybacks represent the cash spent repurchasing the company's own shares. Buybacks reduce shares outstanding and can increase EPS.

Share Buybacks's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Share Buybacks's Fluicell historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Fluicell

All Key Metrics — Fluicell